Royalty Pharma Says Synthetic Royalties Still Just 5% Penetrated as RevMed-Style Deals Draw Wave of Inbound Interest
Bank of America Global Healthcare Conference, September 23, 2026
Royalty Pharma's leadership used a fireside chat at Bank of America's Global Healthcare Conference to lay out a capital deployment framework more expansive than its public guidance suggests, while disclosing that the company's synthetic royalty business — the innovative financing structure behind its landmark Revolution Medicines deal — still commands only about 5% share of the small and mid-cap biotech financing market. CFO Terry Coyne and Managing Director of Partnering Greg Butz spent 40 minutes with BofA's Richard Wagner covering everything from China royalty strategy to leverage ceilings, and the tone throughout was one of a company sitting on more capital and more opportunity than its guidance implies.
RevMed structure emerges as a repeatable alternative to pharma partnerships
The most consequential disclosure centered on the Revolution Medicines transaction, which Royalty Pharma structured to fund late-stage development and independent commercialization without RevMed needing to strike a traditional partnership with big pharma. Coyne called it unprecedented: "It's unique. It's the first time that you've seen a true scaled alternative to pharma." Historically, biotech companies facing a launch decision either raised dilutive equity or sold themselves into a partnership with a large pharmaceutical company. Royalty Pharma's synthetic royalty structure offers a third path — lower-cost, less dilutive capital that lets management teams delay or avoid the partnership decision entirely.
Management said the deal has already generated a meaningful pickup in inbound interest from other companies facing similar late-stage capital needs, and confirmed the firm has the balance sheet to pursue multiple similarly sized transactions concurrently. Butz was explicit that there is no natural ceiling to how large this could become for the portfolio: "At this point, we don't see an upper bound. We're about 5% share of the market. Synthetic royalties for small mid-cap biotech companies are 5% share. It's nothing." He added that competition is coming less from other royalty buyers and more from alternative capital sources — equity, convertible debt, and licensing dollars — putting Royalty Pharma in the position of arguing its cost of capital against those options rather than against rival specialty financiers.
Coyne noted that royalties made up 20% to 30% of total capital raised in prior transactions like Revolution Medicines, Cytokinetics, Immunomedics, and the original Biohaven financing, describing that mix as "a road map for the industry" — royalties as a standard component of biotech capital structures rather than a niche tool.
China strategy still excluded from guidance, but team-building is underway
Royalty Pharma disclosed that it has hired Ken Sun from Morgan Stanley to build out a local presence in Hong Kong, mirroring the approach the firm took when it expanded into Western markets over the past 25 years. The strategy is focused specifically on passive royalties retained by Chinese biotech companies against assets that have been licensed to Western multinationals — a pool that has expanded rapidly as U.S. and European pharma companies have sourced innovation from China over the last five to six years. Coyne was clear that this business is not yet included in the firm's $2 billion to $2.5 billion annual capital deployment target, calling it a longer-term opportunity still in the education and relationship-building phase. On the question of whether Chinese out-licensing royalties carry structurally higher yields than traditional academic royalties, management pushed back on the idea of an "excess return," attributing higher rates instead to the later-stage, de-risked nature of the assets: "As you move into the clinic and you have proof of concept and you have a validated target, you're able to get a higher royalty... there has been a level of de-risking along the way."
On geopolitical risk, Coyne argued that because royalty structures sit outside China and the underlying products are commercialized by Western marketing partners, near-term deal activity is unlikely to be disrupted by U.S.-China policy shifts, though he acknowledged that a slowdown in Western in-licensing of Chinese assets over the longer term "is possible."
Capital deployment guidance framed as deliberately conservative
Management reiterated that the $2 billion to $2.5 billion annual deployment target is a floor rather than an aspiration. Coyne said the firm evaluated roughly 400 opportunities last year and closed just 8 transactions, a hit rate near 2%, underscoring that the constraint is deal quality, not capital availability. "We're not in that business" of forcing deployment to hit a number, he said, adding that doing so "would impact returns" and "would impact probabilities of success." The implication for investors is that upside to the $2 billion to $2.5 billion figure is a function of opportunity flow, not capacity — and management believes that flow has been strong.
Portfolio concentration set to decline meaningfully by decade's end
Coyne offered a specific data point on diversification: the top 3 royalty streams currently represent about 45% of Royalty Pharma's top line, versus roughly 55% for a typical large pharma company. By the end of the decade, management expects that figure to fall to around 30%, while pharma peers remain closer to 50%. He also highlighted that the diversification benefit flows through to the bottom line as well — unlike pharma companies, where a handful of blockbusters disproportionately drive profit, Royalty Pharma's earnings mix mirrors its revenue mix, reducing the earnings volatility tied to any single asset.
Loss of exclusivity has repeatedly been absorbed without denting growth
Management pointed to a track record of growing through major patent cliffs as evidence the model can withstand single-asset losses. The company lost its fourth-largest royalty stream, Gilead's HIV franchise, in 2021, and its fifth-largest, Merck's Januvia, in 2022, yet still posted a 13% compound annual growth rate in cash flow per share from 2020 to 2025. A 2025 loss of exclusivity is expected to weigh through 2026, with a U.S. generic entry for Xtandi expected in late summer 2027 creating a modest fourth-quarter impact that year. Beyond that, Coyne said the portfolio should see relatively clean growth through the remainder of the decade.
Leverage ceiling and buyback discipline quantified
Asked directly about balance sheet limits, management said Royalty Pharma — now rated BBB by all three major credit agencies — would not take leverage above 4 times debt to adjusted EBITDA except for an exceptionally compelling opportunity, and even then would need visibility into rapid deleveraging. Current leverage sits around 2.8 times. On capital returns, Coyne detailed a dynamic buyback approach: the firm repurchased $1 billion of stock in the first half of 2025 when shares were viewed as depressed and deal flow was slower, then throttled back buybacks in the second half of the year as the Revolution Medicines transaction and an industrial royalty purchase from P1 absorbed capital. In total, the company has bought back roughly $2 billion of stock at prices in the $30 per share range, versus a current share price near $60.
2030 cash flow target framed as achievable independent of Vertex arbitration
Royalty Pharma's guidance of $7.50 in cash flow per share by 2030 does not assume a downside outcome in its pending Vertex royalty arbitration, Coyne clarified, but management is confident the target is reachable regardless of how that dispute resolves in the first half of 2027. He cited strong recent performance from Tremfya, Orladeyo, and Trelegy, along with anticipation around the daraxonrasib launch, as reasons for confidence a year after the guidance was first issued.
Pipeline catalysts concentrated in immunology and cardiovascular
Among near-term readouts, management flagged Biogen's litifilimab in cutaneous and systemic lupus by year-end, with additional mechanistic data expected into 2027, as well as frexalimab in multiple sclerosis. On the cardiovascular side, full data for pelacarsen — which already delivered a disappointing headline outcome — is expected to carry read-through implications for olpasiran, a longer-dated Lp(a) asset not expected to read out until roughly 2028.
AI investment aimed at diligence depth, not deal volume
Royalty Pharma hired an AI lead earlier this year from IQVIA, where the executive ran the data giant's AI efforts, signaling a more serious institutional push into using AI for deal diligence. Coyne was careful to frame the payoff as qualitative rather than a throughput story: the technology is expected to deepen forecasting accuracy and accelerate processing of partner data rather than simply increase deal count. Longer term, management sees AI evolving into a service offered to biotech and pharma partners themselves — for clinical trial design, for instance — reinforcing the firm's positioning as a strategic partner rather than a pure capital provider.